Literature DB >> 27088374

Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant.

M Ueda1,2, M de Lima1,2, P Caimi1,2, B Tomlinson1,2, J Little1,2, R Creger1,2, H Lazarus1,2, B Cooper1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27088374     DOI： 10.1038/bmt.2016.104

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

Review 1.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

Authors:  Shannon L Maude; David T Teachey; David L Porter; Stephan A Grupp
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

2.  Successful reinduction of patients with acute lymphoblastic leukemia who relapse following bone marrow transplantation.

Authors:  B Bostrom; W G Woods; M E Nesbit; W Krivit; J Kersey; D Weisdorf; R Haake; A I Goldman; N K Ramsay
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

3.  Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases.

Authors:  F Frassoni; A J Barrett; A Grañena; P Ernst; G Garthon; H J Kolb; H G Prentice; J P Vernant; F E Zwaan; A Gratwohl
Journal:  Br J Haematol       Date:  1988-11       Impact factor: 6.998

4.  FDA Approval: Blinatumomab.

Authors:  Donna Przepiorka; Chia-Wen Ko; Albert Deisseroth; Carolyn L Yancey; Reyes Candau-Chacon; Haw-Jyh Chiu; Brenda J Gehrke; Candace Gomez-Broughton; Robert C Kane; Susan Kirshner; Nitin Mehrotra; Tiffany K Ricks; Deborah Schmiel; Pengfei Song; Ping Zhao; Qing Zhou; Ann T Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2015-09-15       Impact factor: 12.531

5.  Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study.

Authors:  S-J Choi; J-H Lee; J-H Lee; S Kim; Y-S Lee; M Seol; S-G Ryu; J-S Lee; W-K Kim; S Jang; C-J Park; H-S Chi; K-H Lee
Journal:  Bone Marrow Transplant       Date:  2005-07       Impact factor: 5.483

6.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Authors:  Max S Topp; Nicola Gökbuget; Anthony S Stein; Gerhard Zugmaier; Susan O'Brien; Ralf C Bargou; Hervé Dombret; Adele K Fielding; Leonard Heffner; Richard A Larson; Svenja Neumann; Robin Foà; Mark Litzow; Josep-Maria Ribera; Alessandro Rambaldi; Gary Schiller; Monika Brüggemann; Heinz A Horst; Chris Holland; Catherine Jia; Tapan Maniar; Birgit Huber; Dirk Nagorsen; Stephen J Forman; Hagop M Kantarjian
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

7.  Donor leukocyte infusions in acute lymphocytic leukemia.

Authors:  R H Collins; S Goldstein; S Giralt; J Levine; D Porter; W Drobyski; J Barrett; M Johnson; A Kirk; M Horowitz; P Parker
Journal:  Bone Marrow Transplant       Date:  2000-09       Impact factor: 5.483

Review 8.  Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.

Authors:  A W Loren; D L Porter
Journal:  Bone Marrow Transplant       Date:  2007-11-19       Impact factor: 5.483

9.  Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy.

Authors:  J Mortimer; M A Blinder; S Schulman; F R Appelbaum; C D Buckner; R A Clift; J E Sanders; R Storb; E D Thomas
Journal:  J Clin Oncol       Date:  1989-01       Impact factor: 44.544

10.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Authors:  Francesco Lo-Coco; Giuseppe Avvisati; Marco Vignetti; Christian Thiede; Sonia Maria Orlando; Simona Iacobelli; Felicetto Ferrara; Paola Fazi; Laura Cicconi; Eros Di Bona; Giorgina Specchia; Simona Sica; Mariadomenica Divona; Alessandro Levis; Walter Fiedler; Elisa Cerqui; Massimo Breccia; Giuseppe Fioritoni; Helmut R Salih; Mario Cazzola; Lorella Melillo; Angelo M Carella; Christian H Brandts; Enrica Morra; Marie von Lilienfeld-Toal; Bernd Hertenstein; Mohammed Wattad; Michael Lübbert; Matthias Hänel; Norbert Schmitz; Hartmut Link; Maria Grazia Kropp; Alessandro Rambaldi; Giorgio La Nasa; Mario Luppi; Fabio Ciceri; Olimpia Finizio; Adriano Venditti; Francesco Fabbiano; Konstanze Döhner; Michaela Sauer; Arnold Ganser; Sergio Amadori; Franco Mandelli; Hartmut Döhner; Gerhard Ehninger; Richard F Schlenk; Uwe Platzbecker
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245
  10 in total
  4 in total

Review 1.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 2.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Blood Adv       Date:  2017-11-28

3.  Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.

Authors:  Mahmoud R Gaballa; Pinaki Banerjee; Denái R Milton; Xianli Jiang; Christina Ganesh; Sajad Khazal; Vandana Nandivada; Sanjida Islam; Mecit Kaplan; May Daher; Rafet Basar; Amin Alousi; Rohtesh Mehta; Gheath Alatrash; Issa Khouri; Betul Oran; David Marin; Uday Popat; Amanda Olson; Priti Tewari; Nitin Jain; Elias Jabbour; Farhad Ravandi; Hagop Kantarjian; Ken Chen; Richard Champlin; Elizabeth Shpall; Katayoun Rezvani; Partow Kebriaei
Journal:  Blood       Date:  2022-03-24       Impact factor: 22.113

Review 4.  Bispecific Antibodies and Other Non-CAR Targeted Therapies and HSCT: Decreased Toxicity for Better Transplant Outcome in Paediatric ALL?

Authors:  Krisztián Miklós Kállay; Mattia Algeri; Jochen Buechner; Aviva C Krauss
Journal:  Front Pediatr       Date:  2022-02-02       Impact factor: 3.418
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.